31.03.2026

Insights and Lessons Learned: Highlights from the MAINFRAME 2026 Symposium

by: SGC

A Community Taking Shape in AI-Driven Drug Discovery

In March 2026, the first MAINFRAME Symposium brought together more than 180 researchers from academia and industry in Barcelona, marking a defining moment for a rapidly emerging field. What began just over a year ago as an idea to create an open, global community focused on machine learning for drug discovery has quickly evolved into a growing international network now spanning more than 250 members across 45+ countries.

Postdoctoral Research Associate (SGC-UNC)

Position Information

A global higher education leader in innovative teaching, research and public service, the University of North Carolina at Chapel Hill consistently ranks as one of the nation’s top public universities and is among is the top ten research universities in the nation for federal research expenditures as well as for federally funded social and behavioral sciences research and development.

Target 2035 Fellow (Postdoctoral Researcher – Community Benchmarking & Critical Assessment)

Supervisor(s): Position 1: Benjamin Sanchez-Lengeling (University of Toronto), Pablo Meyer (IBM Research) and Gustavo Stolovitzky (NYU Langone) | Position 2:  John Moult (University of Maryland) and Matthieu Schapira (SGC)

Program: Mitacs Accelerate – Target 2035 Fellows

Location: Toronto, Canada

13.02.2026

Partnering to accelerate early drug discovery in Australia

by: SGC

GRIFFITH-February 17, 2026 - Compounds Australia (Griffith University), Australia’s national compound management facility, and the  Structural Genomics Consortium (SGC) are excited to announce a new partnership to enable access to high-quality chemical probes to accelerate early drug discovery research. Through this partnership, the SGC’s Donated Chemical Probes (DCP) library is now part of the open access compound collection of Compounds Australia. 

10.02.2026

New Open Science Project Funded to Accelerate Therapeutic Discovery for Spinal Bulbar Muscular Atrophy

by: SGC

Toronto, ON, Canada — Agora Open Science Trust, in collaboration with the Structural Genomics Consortium (SGC) and an international team of academic researchers, is pleased to announce the launch of a new one-year research project funded by Kennedy’s Disease Association (KDA). This new grant seeks to accelerate the development of targeted therapeutic strategies for Spinal Bulbar Muscular Atrophy (SBMA), a rare neuromuscular disorder with no drugs to slow or halt disease.

Subscribe to